Metabonomics analysis of intravitreal injection of anti-vascular endothelial growth factor drugs in the treatment of macular edema secondary to branch retinal vein occlusion
SUN Yining1, YANG Chun1, 2,HUANG Ying1, 2, GE Lina1, 2, JIANG Dan1, 3, LIN Bing1, 2
1.School of Ophthalmology & Optometry,Biomedical Engineering, Wenzhou Medical University, Wenzhou 325027, China; 2.Fundus Medicine Department,Eye Hospital of Wenzhou Medical University, Wenzhou 325027, China; 3.Corneal and Ocular Surface Disease Specialist, Eye Hospital of Wenzhou Medical University, Wenzhou 325027, China
SUN Yining,YANG Chun,HUANG Ying, et al. Metabonomics analysis of intravitreal injection of anti-vascular endothelial growth factor drugs in the treatment of macular edema secondary to branch retinal vein occlusion[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2023, 53(4): 285-290.
Abstract：Objective: To investigate the intraocular metabolic changes in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO) treated with intravitreal injection of vascular endothelial growth factor antagonist (anti-VEGF). Methods: The aqueous humor samples of 20 patients with ME secondary to BRVO were collected from Eye Hospital of Wenzhou Medical University during January 2021 to June 2021,before anti-VEGF treatment and 1 month after treatment, which were analyzed by liquid chromatography/mass spectrometry (LC-MS/MS) technology to detect metabolites, and metabolites were screened and functionally annotated by principal component analysis (PCA), differential metabolite analysis and pathway enrichment analysis. Results: After 1 month of anti-VEGF treatment, the central macular thickness of all ME secondary to BRVO patients was decreased with statistically significance (P<0.05). PCA results showed that metabolites of aqueous humor in patients with ME secondary to BRVO were significantly different from those before treatment.An analysis of differential metabolites found that the content of 4-Oxo-2-nonenal in the aqueous humor of patients after treatment was significantly increased (P<0.05), while palmitoyl lysophosphatidylcholine PC (16:0),7-ene and the contents of metabolites such as chol(ster)alkanol and PC[20:4(8Z, 11Z, 14Z, 17Z)/P-18:0] were significantly decreased (P<0.05). The pathway enrichment analysis showed that metabolites with reduced content were mainly involved in biological processes such as glycerophospholipid metabolism, α-linoleic acid metabolism and linolenic acid metabolism (P<0.05). Conclusion: ME secondary to BRVO patients showed significant changes in the intraocular metabolism after anti-VEGF treatment, with significant decrease in lipid metabolism.
